Quarterly ResultMay 12, 2026, 04:15 PM
Lineage Cell Therapeutics Q1 Net Loss $(4.8)M; Launches COR1 Program
AI Summary
Lineage Cell Therapeutics reported a net loss of $(4.8) million for Q1 2026, an increase from $(4.1) million in Q1 2025, with total revenues rising to $1.7 million. The company also announced significant business advancements, including positive 3-year Phase 1/2a clinical data for OpRegen, the launch of its new COR1 corneal endothelial disease cell therapy program, and the treatment of a second patient in the OPC1 DOSED study. Additionally, Lineage established a Scientific Advisory Board and appointed a new SVP & Head of Clinical. The company expects its cash to support operations into Q2 2028.
Key Highlights
- Launched COR1, a new preclinical corneal endothelial cell therapy program for Fuchs Endothelial Corneal Dystrophy.
- Reported positive 3-year Phase 1/2a clinical data for RG6501 (OpRegen ), showing sustained visual acuity gains.
- Treated the second chronic SCI patient in the OPC1 DOSED device safety study.
- Achieved the first milestone in the AlloSCOPE 5D manufacturing initiative for scalable pluripotent cell production.
- Q1 2026 total revenues increased to $1.7 million from $1.5 million in Q1 2025.
- Q1 2026 net loss attributable to Lineage was $(4.8) million, compared to $(4.1) million in Q1 2025.
- Cash, cash equivalents, and marketable securities totaled $53.4 million as of March 31, 2026.
- Cash runway is expected to support planned operations into Q2 2028.